1. Home
  2. AGL vs INDP Comparison

AGL vs INDP Comparison

Compare AGL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo agilon health inc.

AGL

agilon health inc.

HOLD

Current Price

$10.74

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.60

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGL
INDP
Founded
2016
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
4.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
AGL
INDP
Price
$10.74
$1.60
Analyst Decision
Hold
Analyst Count
13
0
Target Price
$66.48
N/A
AVG Volume (30 Days)
3.8M
17.3K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,932,576,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.27
52 Week High
$9.80
$13.24

Technical Indicators

Market Signals
Indicator
AGL
INDP
Relative Strength Index (RSI) 96.91 37.58
Support Level $0.69 $0.27
Resistance Level N/A $1.99
Average True Range (ATR) 0.39 0.11
MACD 1.12 -0.00
Stochastic Oscillator 97.82 7.14

Price Performance

Historical Comparison
AGL
INDP

About AGL agilon health inc.

Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: